NCI Seeks New Technologies

NCI Seeks New Technologies

October 1, 1998

Publication

Article

Oncology NEWS InternationalOncology NEWS International Vol 7 No 10

Volume 7

Issue 10

BETHESDA, Md--The National Cancer Institute (NCI) is seeking technology systems to revolutionize cancer detection, diagnosis, and treatment. Under a new $48 million, 5-year program dubbed the Unconventional Innovations Program, NCI is looking for new technologies "that will enable sensing of molecular alterations in the body in a way that is highly sensitive and specific, yet nonintrusive."

NCI has requested input from molecular and cellular biologists, engineers, physicists, chemists, and computational biologists who can point to new directions for research. Information obtained will be used to outline government research goals that will be issued in late 1998 or early 1999, followed by requests for specific research proposals.

Articles in this issue

Panel Recommends Photofrin for Use in Late-Stage Lung Cancer

California Intervention Raises Consumption of Fruits and Vegetables

ODAC Panel Okays Nolvadex to Reduce Breast Cancer Risk

Evolving Role for Preoperative Chemo in Breast Cancer

NCI Sets Sail on a New Tack In the Stormy Seas of CAM

Opioid Antagonists Can Control Opioid-Induced Constipation

NCI Seeks New Technologies

View Cancer Pain as a Pathogenic Agent to be Treated, Expert Says

NIAID Collaborates With VaxGen, Inc. on Trials of AIDSVAX

Clinicians Often Fail To Provide Adequate Genetic Counseling

Networks Assist Community Oncologists in Research Quest

Three Months After Voting Nay, ODAC Backs Valstar Approval

M.D. Anderson Center Will Consolidate Faculty Offices in New Building in 2000

Drug-Seeking Behavior in Pain Patients Rarely Addiction

Device Finds Breast Lesions by Measuring Electropotentials

Related Content

The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.

Neoadjuvant/Adjuvant Pembrolizumab Regimens Lower RCB in ER+ Breast Cancer

April 19th 2024

Article

The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

April 15th 2024

Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

FDA Mandates New CAR T-Cell Therapy Boxed Warnings in Hematologic Cancers

April 19th 2024

Article

The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

April 8th 2024

Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

FDA Approves Alectinib for Early-Stage ALK+ NSCLC

April 18th 2024

Article

The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or node positive, as detected by an FDA-approved test.